Organization
Early Phase Trials Unit, Institut Bergonié and University of Bordeaux, Bordeaux, France
5 abstracts
Abstract
Tumor fraction to improve patient selection for oncology early phase clinical trials: Analysis of two precision medicine studies.Org: Early Phase Clinical Trials Unit and Thoracic Unit, Institut Bergonié, Bordeaux, France, Bergonie Institute, Inserm CIC1401, Bordeaux, France, Institut Bergonié, Molecular Biology Department, Bordeaux, France, Molecular Pathology Unit-Department of Biopathology, Institut Bergonié, Bordeaux, France, Institut Bergonie, Molecular Biology Department, Bordeaux, France,
Abstract
Correlation of immune phenotypes derived from H&E-stained whole slide images with prognosis and response to checkpoint inhibitors in NSCLC.Org: PathAI, Incendia Therapeutics, Explicyte Immuno-Oncology, Institut Bergonié, Early Phase Trials Unit, Institut Bergonié and University of Bordeaux, Bordeaux, France,
Abstract
A phase 2 multi-arm study of magrolimab in combination with docetaxel in patients with locally advanced or metastatic solid tumors: ELEVATE Lung and UC.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Rogel Cancer Center, University of Michigan, Huntsman Cancer Center, Oregon Health and Science University, Hospital Virgen del Rocio, Seville, Spain,
Abstract
Larotrectinib long-term efficacy and safety in adult patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer.Org: University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, Division of Medical Oncology, National Cancer Center Singapore and Duke-NUS Medical School, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Oregon Health and Science University,
Abstract
TROP2 expression and response to immune checkpoint inhibition in patients with advanced non-small cell lung cancer.Org: Early Phase Trials Unit, Institut Bergonié and University of Bordeaux, Bordeaux, France, Institut Bergonié, University of Bordeaux, Bergonié Institute, ImmuSmol,